The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Pirfenidone is currently marketed as Esbriet for the treatment of idiopathic pulmonary fibrosis in adults.
Better adherence to medication is associated with improved health-related quality of life in sarcoidosis.
Individuals with HIV were more likely to have interstitial lung abnormalities and findings suspicious for the presence of interstitial lung disease than individuals without HIV.
Bellerophon Therapeutics announced positive topline results from cohort 2 of a study of INOpulse delivery system for PH-ILD.
Higher adiponectin levels are associated with lower high attenuation areas, a computed tomography-based measure of subclinical interstitial lung disease.
Researchers of the study aimed to determine the differences in muscle area and bone density in patients with end-stage lung disease.
The FDA has granted Breakthrough Therapy designation to nintedanib for the treatment of chronic fibrosing ILDs with a progressive phenotype.
Although the planned statistical model could not be applied to primary end point data, key secondary end point analysis suggested that patients with progressive fibrosing unclassifiable interstitial lung disease could benefit from pirfenidone.
Nintedanib was linked to a lower rate of decline in forced vital capacity vs placebo in a phase 3 trial.
